Catherine Coughlin

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Neuropsychopharmacology August 29, 2017 Jerome H Taylor, Angeli Landeros‐Weisenberger, Catherine Coughlin et al.

Many patients with social anxiety disorder (SAD) experience inadequate symptom relief from available treatments. Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared the...